According to a research report from Guotai Haitong, the global multiport laparoscopic surgical robot installations are projected to reach nearly 30,000 units by 2033, with the market size expected to hit $238 billion. In 2024, the penetration rate of robot-assisted laparoscopic surgeries was 21.9% in the United States, while it stood at only 0.7% in China, indicating significant room for growth. Clinical trial data currently show that domestically produced surgical robots match the effectiveness and safety of the Da Vinci system, with the added advantage of being more cost-effective. Furthermore, Chinese manufacturers have achieved several world-first breakthroughs in areas such as remote surgery and integrated single-port, multi-port, and remote systems, establishing a differentiated competitive edge. Key insights from Guotai Haitong include the following: Surgical robots offer clinical advantages that are driving increased adoption and rapid global market expansion. Robot-assisted surgeries help overcome human physiological limitations, providing higher precision, stability, and repeatability, which translate into significant clinical benefits. Driven by technological advancements, benefits for both surgeons and patients, and supportive government policies, the global laparoscopic surgical robot market is growing swiftly. By 2033, global installations of multiport laparoscopic surgical robots are forecast to approach 30,000 units, with the market size reaching $238 billion. The compound annual growth rate for installations from 2024 to 2033 is estimated at 12.2%, while the market size is expected to grow at a CAGR of 10.9%. Intuitive Surgical, the global leader in surgical robotics, was founded in 1995 and installed its first Da Vinci surgical robot in 1998. It took a decade to surpass 1,000 global installations by 2008. Early growth was driven by clinical advantages in radical prostatectomy, which accelerated adoption in the U.S. and helped build a consumables-driven revenue model. By 2025, Intuitive Surgical had installed a cumulative total of 11,106 Da Vinci robots, generating over $100 billion in revenue and more than $30 billion in net profit. Initially focused on direct sales in North America and Western Europe, the company began expanding its direct sales network into Asia-Pacific and other European regions from 2012 onward. As international expansion continued, the proportion of revenue and installations from outside the U.S. steadily increased. By 2025, non-U.S. markets accounted for over 30% of the company’s revenue and more than 40% of annual installations. Growth in procedure volume outside the U.S. reached approximately 23%, outpacing domestic growth. Domestic manufacturers are leveraging cost-effectiveness and differentiation strategies to accelerate global commercialization. Clinical trial data indicate that Chinese-made surgical robots are comparable to the Da Vinci system in terms of efficacy and safety, while offering greater affordability. Chinese manufacturers have also achieved multiple world-first innovations in remote surgery and integrated single-port, multi-port, and remote systems, strengthening their competitive positioning. Since 2025, overseas orders and revenue for domestic surgical robot companies have grown rapidly. MEDBOT-B (02252) reported overseas sales revenue of RMB 400 million, a year-on-year increase of 287%. EDGE MEDICAL-B (02675) generated RMB 270 million in sales to end-users outside China, accounting for nearly 60% of its total revenue. These figures reflect the accelerating pace of global commercialization for Chinese surgical robot makers. Potential risks include delays in research and development, slower-than-expected commercialization, and geopolitical uncertainties.
Comments